

Referances

- **Abhijat S, John P, Yee O** et al., Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. *Vascul Pharmacol.* 2005 ;42:41-45.
- **Aguilar RV, Farber HW, Timothy B** et al., Epoprostenol (prostacyclin) therapy in HIV associated pulmonary hypertension. *Am J Respir Crit Care Med.* 2000;161:2142-2155.
- **Alloggiamento T, Zipp C & Froelicher VF** et al., Sex, the heart, and sildenafil. *Current Problems in Cardiology*, (2001). 26: 388-415.
- **Andrew J , Anne K, Christopher H** et al., Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation *Journal of the American College of Cardiology* 2010 55: 380 - 407.
- **Arcasoy SM, Christie JD, Ferrari VA**, et al., Echocar-diographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Med* 2003; 167: 735-740.
- **Arora RR, Timoney M & Melilli L** et al., Acute myocardial infarction after the use of sildenafil. *New England Journal of Medicine*, (1999). 341:3252-3270.
- **Aubin C, Webster L, Rebeyka IM** et al., Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. *Circulation* 2007 ;116 :238-248.

Referances

- **Badesch DB, Abman SH, Ahearn GS** et al., Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. *Chest*. 2004;126: 35S–62S
- **Badesch DB, Tapson VF, McGoon MD** et al., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. *Ann Intern Med*. 2000;132:322-334.
- **Ballard SA, Gingell CJ, Tang K,** et al., Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. *J Urol* 1998 ; 159:2164-2171,
- **Barst RJ, Langleben D, Frost A** et al., Sitaxsentan therapy for pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2004;169:1125-1239.
- **Barst RJ, McGoon MD, McLaughlin VV** et al., Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol*. 2003;108:775-784.
- **Barst RJ, McGoon M, Torbicki A** et al., Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43:S40–S47.
- **Barst RJ, Rubin LJ, Long WA** et al., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med*. 1996;331:2237-2243.
- **Bharani A, Mathew V, Sahu A,** et al: The efficacy and tolerability of sildenafil in patients with moderate to severe pulmonary hypertension. *Indian Heart J J* 2003; 55:55-59.
- **Bhatia S, Frantz RP, Severson CJ,** et al: Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with

Referances

pulmonary arterial hypertension receiving vasodilator therapy. *Mayo Clin Proc* , 2003;78:1207- 1213.

- **Bocchi EA, Guimaraes G, Mocelin A**, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebocontrolled, randomized study followed by a prospective treatment for erectile dysfunction. *Circulation* 2002; 106:1097–1103.
- **Bossone E, Rubenfire M, Bach DS** et al.,Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 1999;34:525-536.
- **Bourlaug BA, Melenovsky V, Marhin T** et al., Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. *Circulation* 2005;112;2320-2328.
- **Brendan P. Madden, Mark A, Tuck-Kay L** et al., A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease *Madden* 2006;44:188-197.
- **Brendan P, Abhijat S, Mike W**, et al.,Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?.*Madden* 2007;47:147-151.
- **Budhiraja R, Tuder RM, Hassoun PM** et al., Endothelial dysfunction in pulmonary hypertension. *Circulation* 2004;109:1161-1169.
- **Caraballo Fonseca JC, Martinez CD, Sanchez R** et al., Endothelial dysfunction in pulmonary hypertension. *Arch Bronconeumol* 2005;41:236-241.
- **Carson III CC** : Sildenafil: a 4-year update in the treatment of 20

Referances

- million erectile dysfunction patients. *Current Urology Reports*, (2003); 4: 488-496.
- **Channick RN, Simonneau G, Sitbon O** et al., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet*. 2001;356:1103-1116.
 - **Chapman M. Wilde, A. Sheth, B.P. Madden** et al., Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use? *Vascular Pharmacology* 2009;51: Pages 90-95.
 - **Chattipakorn N, Fotuhi PC, Chattipakorn SC** et al., Three-dimensional mapping of earliest activation after nearthreshold ventricular defibrillation shocks. *Eur heart J* (2003);2243-2249.
 - **Cheitlin MD, Hutter Jr , Brindis RG,** et al., ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. *Journal of the American College of Cardiology*(1999); 33: 273 - 282.
 - **Chen Y, Du R, Traverse JH,** et al: Effect of sildenafil on coronary active and reactive hyperemia. *Am J Physiol Heart Circ Physiol* 2000;279:H2319-H2325.
 - **Chiang CE, Luk HN, Wang TM** et al., Effects of sildenafil cardiac repolarization. *Cardiovascular Research* (2004);55: 290-299.
 - **Christman BW, McPherson CD, Newman JH** et al., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N Engl J Med*. 1992;327:70–75.

Referances

- **Corbin J, Rannels S, Neal D** et al., Sildenafil citrate does not affect cardiac contractility in human or dog heart. *Euro Heart J* (2003);24:297-299.
- **Dantzker D, Bower J, John J** et al., Hemodynamic Effects of Sildenafil in Patients With Congestive Heart Failure and Pulmonary Hypertension Combined Administration With Inhaled Nitric Oxide, *Circulation* 2005;112:2360-2368.
- **Das A, Ockaili R, Salloum F** et al., Protein kinase C plays an essential role in sildenafil induced cardioprotection in rabbits. *American Journal of Physiology* 2004;286:H1455-H1460
- **Das S, Maulik N, Das DK** et al., Cardioprotection with sildenafil, a selective inhibitor of cyclic 3',5'- monophosphate-specific phosphodiesterase 5. *Drugs under Experimental and Clinical Research* 2002;28,:213-219
- **Degerman E, Belfrage P & Manganiello VC** et al., Structure, localization and regulation of cGMP-inhibited phosphodiesterase (PDE3). *Journal of Biological Chemistry*, 1997;272;6823-6826.
- **Deng Z, Morse JH, Slager SL** et al., Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. *Am J Hum Genetics*. 2000; 67(3): 737–744.
- **Dietz U, Tries HP, Merkle W** et al: Sildenafil does not change coronary flow reserve in diabetics with erectile dysfunction. *Dtsch Med Wochenschr* 2003;128:190-195.
- **Dorfmueller P, Perros F, Balabanian K** et al., Inflammation in pulmonary arterial hypertension. *Eur Respir J*. 2003;22:358–363.

Referances

- **Dubin D, Pratt RE, Dzau VJ** et al.,Endothelin, a potent vasoconstrictor, is a smooth muscle mitogen. *J Vasc Biol Med.* 1989;1:150–154.
- **Du L, Sullivan C, Chu D** et al.,Signaling molecules in nonfamilial pulmonary hypertension. *N Engl J Med.* 2003; 348:500-509.
- **Eddahibi S, Humbert M, Fadel E** et al.,Hyperplasia of pulmonary artery smooth muscle cells is causally related to over expression of the serotonin transporter in primary pulmonary hypertension. *Chest* 2002 ;121:97S-98S.
- **Eddahibi S, Humbert M, Fadel E** et al.,Serotonin transporter over expression responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. *J Clin Invest.* 2001;108::1141-1150.
- **European Medicines Agency.** Revatio:product information Schermuly RT, Pullamsetti SS, Kwapiszewska G, et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. *Circulation* 2007 15(17):2331-2339.
- **Fedullo PF, Auger WR, Kerr KM** et al.,Chronic thromboembolic pulmonary hypertension. *N Engl J Med* 2001;345:1465 – 1472.
- **Fisher MR, Forfia PR, Chamera E** et al.,Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Resp Crit Care Med* 2009; 179:615-621.
- **Fuster V, Frye RL, Gersh BJ** et al., Primary pulmonary hypertension: natural history and the importance of thrombosis 1984 *Circulation*;70:580-587.

Referances

- **Gaine SP, Rubin LJ , Simonneau G** et al.,Primary pulmonary hypertension Lancet 1999;353:740-752.
- **Galie N, Badesch DB, Oudiz R** et al.,Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46:529-535.
- **Galiè N, Brundage BH, Ghofrani HA,** et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894-2903.
- **Galie` N, Ghofrani HA, Torbicki A** et al., Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-2157.
- **Galie N, Humbert M, Vachiery J** et al.,Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002 ;39:1496-1502.
- **Galie N, Kim NHS , Levy R** et al., Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:571-576.
- **Galiè N, Manes A, Palazzini M** et al.,Management of pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts and Eisenmenger's syndrome. Drugs 2008 ;68:1049-1066.
- **Galie N, Torbicki A, Barst R** et al., Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-2278.
- **Geelen P, Drolet B, Rail J** et al., Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation, 2000;102:275-277.

Referances

- **George D, Knight C, Davar J** et al., Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology* 2004;43:461-466.
- **Ghada W, Sanjay K, Wei L** et al., Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and midterm effects, *Euro Heart J* 2004;25:431;436.
- **Ghofrani HA, Osterloh IH, Grimminger F** et al., Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. *Nat Rev Drug Discov* 2006; 5:689-702.
- **Ghofrani HA, Rose F, Schermuly RT**, et al: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol* 2003;42:158-164.
- **Ghofrani HA, Schermuly RT, Rose F**, et al: Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med* 2003; 1667:1139-1141.
- **Ghofrani HA, Wiedemann R, Rose F**, et al: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial *Lancet* 200; 360:895-900.
- **Giaid A, Saleh D, Michel R** et al., Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. *N Engl J Med.* 1995;333:214 –221.
- **Giaid A, Yanagisawa M, Langleben D** et al., Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med.* 1993;328:1732–1739.

Referances

- **Gibbons GH, Shennib H, Shizukuda Y** et al., Endothelial function as a determinant of vascular function and structure: a new therapeutic target. *Am J Cardiol* 1997 ;79:3-8.
- **Gillies HC, Roblin D, Jackson G** et al., Coronary and systemic hemodynamic effects of sildenafil citrate: From basic science to clinical studies in patients with cardiovascular disease. *Int J Cardiol* 86:131-141, 2002
- **Gladwin MT, Sachdev V, Jison ML** et al., Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *N Engl J Med* 2004;350:886 – 895
- **Goldstein I, Lue TF, Padma-Nathan H** et al., Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *New England Journal of Medicine* 1999;281:421-426.
- **Gomberg M, Tapson VF, Benza RL** et al., Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. *Am J Respir Crit Care Med.* 2005;173:499-505.
- **Gregory D, Ravi S, Khurram S** et al., Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Circulation. 2007 ;16:1555-1562.
- **Gross GJ, Negro L, Marinelli A,** et al., The role of mitochondrial KATP channels in cardioprotection. *Basic Research in Cardiology*, 2000;95:285-289.
- **Guimaraes G, V.M. d'Avila, P. Pires** et al., Acute Effects of a Single Dose of Phosphodiesterase Type 5 Inhibitor (Sildenafil) on Systemic Arterial Blood Pressure During Exercise and 24-Hours Ambulatory

Referances

Blood Pressure Monitoring in Heart Transplant Recipients
2007;39:3142-3149.

- **Hachulla E, Gressin V, Guillevin L** et al., Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. *Arthritis Rheum* 2005 ;52:3792-800.
- **Hatano S, Strasser T.** World Health Organization 1975. Primary pulmonary hypertension Geneva: WHO; 1975.
- **Herrmann HC, Chang G, Klugherz BD** et al., Hemodynamic effects of sildenafil in men with severe coronary artery disease. *New England Journal of Medicine*(2000);342:1622-1626.
- **Hirata K, Adji A, Vlachopoulos C** et al., Effect of sildenafil on cardiac performance in patients with heart failure. *Am J Cardiol* 2005;96:1436:1439.
- **Hoepfer MM, Schwarze M, Ehlerding S** et al ., Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. *N Engl J Med.* 2000;342:1760-1765.
- **Hosseini A, Ghofrani, Ralph T. Schermuly** et al., Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension et al., *American Journal of Respiratory and Critical Care Medicine* 2003; 167: 1139-1141.
- **Humbert M, Barst RJ, Robbins IM** et al., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J.* 2004 ;24:353-359.
- **Humbert M, Morrell NW, Archer SL** et al., Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004;43:S13 – S24.

Referances

- **Ichinose F, Erana-Garcia J, Hromi J**, et al: Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. *Crit Care Med* 2001 ; 29:1000-1005.
- **Ishikura F, Beppu S, Hamada T**, et al: Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. *Circulation* , 2000;102:2516- 2521.
- **Jackson G, Benjamin N, Jackson N**, et al: Effects of sildenafil citrate on human hemodynamics. *Am J Cardiol* 1999;83:13C-20C.
- **Jeffery TK, Wanstall Jc , Gambetti S** et al., Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: Differences between early and established pulmonary hypertension. *J Cardiovasc Pharmacol* 1998;32:213-219.
- **Kanthapillai P, Lasserson T & Walters E** et al., Sildenafil for pulmonary hypertension. *Cochrane Database of Systemic Reviews European Journal of Pediatrics* 2005;164:626-629.
- **Kaya D, Guler C, Esen AM** et al., Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. *Annals of Noninvasive Electro- cardiology* 2004; 9: 228-233.
- **Kleinsasser A, Loeckinger A, Hoermann C**, et al: Sildenafil modulates hemodynamics and pulmonary gas exchange. *Am J Respir Crit Care Med* 2001;163:339-343.
- **Kloner RA , Barutcu I & Dincel C** et al., Cardiovascular risk and sildenafil. *American Journal of Cardiology* 2000;86:652-655.

Referances

- **Kloner RA, Brown M, Prisant LM**, et al: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. *Am J Hypertens* 2001;14:70-73.
- **Kothari SS, Duggal B , Barutcu I** et al., Chronic oral sildenafil therapy in severe pulmonary artery hypertension. *Indian Heart J* 2002;54:404-409.
- **Kovacs G, Berghold A, Scheidl S** et al., Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. *Eur Resp J* 2009; 34:888-894.
- **Krenzelok EP , Olschewski H , Doyle TP** et al., Sildenafil: Clinical toxicology profile. *J Toxicol Clin Toxicol* 2000;38:645- 651.
- **Kuhn KP, Byrne DW, Arbogast PG** et al., Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. *Am J Respir Crit Care Med.* 2002 ;167:580-586.
- **Kulkarni SK, Patil CS, Doyle TP** et al., Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspects. *Methods Find Exp Clin Pharmacol* 2004;26:789 - 799.
- **Lane KB, Machado RD, Pauciuolo MW** et al., Heterozygous germline mutations in *BMPR2*, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension: the International PPH Consortium. *Nat Genetics.* 2000;26:81– 84.
- **Lang IM , Thomson JR, Phillips JA III** et al., Chronic thromboembolic pulmonary hypertension not so rare after all. *N Engl J Med* 2004;350:2236– 2238.
- **Lapa MS, Ferreira EV, Jardim C** et al., Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of

Referances

Sao Paulo. Rev Assoc Med Bras 2006;52:139 – 143.

- **Launay D, Mouthon L, Hachulla E** et al., Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. *J Rheumatol* 2007;34:1105-1110.
- **Lee AJ, Chiao TB, Tsang MP** et al., Sildenafil for pulmonary hypertension. *Ann Pharmacother* 2005;39:869-884.
- **Lepore JJ, Maroo A, Bigatello LM** et al., Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. *Chest*. 2005;127:1647–1653.
- **Lepore JJ, Maroo A, Pereira NL**, et al: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. *Am J Cardiol* 2002; 90:677-680.
- **Leuchte HH, Schwaiblmair M, Baumgartner RA**, et al: Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. *Chest* 2004;125:580-586.
- **Maclean MR, Johnston ED, McCulloch KM**, et al: Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: Changes in pulmonary hypertension. *J Pharmacol Exp Ther* 1997;283:619- 624.
- **Machado RD, Aldred MA, James V** et al., Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. *Hum Mutat* 2006;27:121 – 132.
- **Machado R, Eickelberg O, Elliott CG** et al., Genetics and genomics of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009;54;543-549.

Referances

- **Madden,B.P.,Allenby M,Loke K,Sheth** et al., A Potensial role for Sildenafil in management of pulmonary hypertension in patient with parenchymal lung disease. *Vascular Pharmacology* 2006;44:372-376.
- **Madden,B P .,Hodson,G.M.E.,Tsang V** et al., Intermediate term result of heart lung transplant for cystic fibrosis. *lacent*1992;339:1583-1589.
- **Madden,B.P.,Sheth,A.,Ho,Park,J.E., Kanagasaby,R.R** et al.,Potential role for Slildenafil in the management of perioperative pulmonary hypertension and right bentricular dysfunction.*Br.J. Anaesth.* 2004; 93 :155-156.
- **Manfroi WC, Caramori PR, Zago AJ** et al., Hemodynamic effects of sildenafil in patients with stable ischemic heart disease. *International Journal of Cardiology* 2003;90:153-157.
- Marc Humbert (France); Adam Torbicki (Poland); Jean-Luc Vachiery (France) et al.,Guidelines for the diagnosis and treatment of pulmonary hypertension *European Heart Journal* 2009 ;30: 2493–2537 .
- **Marcos E, Fadel E, Sanchez O** et al.,Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. *Circ Res.* 2004;94:1263–1270.
- **Marsh CS, Marden B, Newsom R** et al., Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. *Br J Ophthalmol* 2004;88:306-307.
- **Matot I, Gozal Y , Khagani A** et al.,Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. *Chest* 2004;125:644-651.
- **McGoon MD, Fuster V, Freeman WK** et al.,The heart and the lungs:

Referances

- pulmonary hypertension. In: Guiliiani ER, Gersh BJ, McGoon MD, Hayes DL, Schaff HV, eds. Mayo Clinic Practice of Cardiology. New York, NY: Mosby Yearbook; 1996
- **McLaughlin VV, Shillington A, Rich S** et al., Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation*. 2002;106:1477-1482.
 - **McLaughlin V, Sitbon O, Badesch DB** et al., Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J*. 2005;60:1025-1030.
 - **McLaughlin VV, Archer SL, Badesch DB**, et al expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 2009; 119:2250-2294.
 - **McQuillan BM, Picard MH, Leavitt M** et al., Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. *Circulation* 2002;106:1162-1168.
 - **Mendeloff EN, Meyers BF, Sundt TM** et al., Lung transplantation for pulmonary vascular disease. *Ann Thorac Surg* 2002;73:209-217.
 - **Michelakis ED, Tymchak W, Noga M** et al ., Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. *Circulation* 2003; 108:2066-2099.

Referances

- **Michelakis E, Tymchak W, Lien D** et al., Oralsildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. *Circulation* 2002; 105:2398-2403.
- **Mikhail GW, Prasad SK, Li W** et al .,Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: Acute and mid-term effects. *Eur Heart J* 2004 ;25:431-436.
- **Morrell N, Adnot S, Archer S** et al., Cellular and molecular basis of pulmonary arterial hypertension. *J Am Coll Cardiol* 2009; 54:S20-31.
- **Murray CJ & Lopez AD** et al.,Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. *Lancet* 1997 ;349:1498-1504.
- **Murry CE, Jennings RB & Reimer KA** et al., Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986;74: 1124-1136.
- **Nagendran J, Archer SL, Soliman D,** et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterasetype 5 improves contractility. *Circulation* 2007; 116:238-248.
- **Nagy O, Hajnal A, Parratt JR** et al., A Sildenafil (Viagra)reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. *British Journal of Pharmacology*, 2004;144:549-551.
- **Naveen G , Mukesh K , Nakul S** et al.,Role of oral sildenafil in severe pulmonary arterial hypertension:Clinical efficacy and dose response relationship *Int J Cardiol.* 2007 ; 120:306-313.

Referances

- **Nony P, Boissel JP, Lievre M** et al., Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta analysis. *European Journal of Clinical Pharmacology* 1994;46:191-196.
- **Olschewski H, Simonneau G, Galie N** et al., Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med.* 2002;347:322-329.
- **Opitz CF, Wensel R, Winkler J** et al., Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. *Eur Heart J.* 2005;26:1895-1902.
- **Otero G, Marina A, Ana S** et al., Clinical Efficacy of Sildenafil in Patients With Pulmonary Hypertension in Functional Class II or III *Arch Bronconeumal* 2006;43;272-276.
- **Oudiz Rj, Inés R, Héctor V** et al., Pulmonary hypertension associated with left-sided heart disease. *ClinChest Med* 2007;28:233-241.
- **Packer M, Carver JR, Rodeheffer RJ** et al Effect of oral milrinone on mortality in severe chronic heart failure. The Promise Study Research Group. *New England Journal of Medicine* 1991 ;325:1468-1475.
- **Padma-Nathan H, Eardley I, Kloner RA** et al., A 4-year update on the safety of sildenafil citrate (Viagra). *Urology* 2002;60:67-90.
- **Paul GA, Gibbs JS, Boobis AR** et al., Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. *Br J Clin Pharmacol* 2005;60:107-112.
- **Peacock AJ, Murphy NF, McMurray JJV** et al., An epidemiological study of pulmonary arterial hypertension. *Eur Respir J* 2007;30:104-109.

Referances

- **Petkov V, Mosgoeller W, Ziesche R** et al., Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. *J Clin Invest.* 2003;11:1339-1346.
- **Phillips BG, Kato M, Pesek CA** et al Sympathetic activation by sildenafil. *Circulation* 2001;102:3068-3073.
- **Pietra GG, Capron F, Stewart S** et al., Pathologic assessment of vasculopathies in pulmonary hypertension. *J Am Coll Cardiol* 2004 ;43(12 Suppl S):25S-32S.
- **Pomeranz HD, Bhavsar AR, Leone O** et al., Nonarteritic ischemic optic neuropath developing soon after use of sildenafil (viagra): A report of seven new cases. *J Neuroophthalmol* 2005 ;25:9-13.
- **Presberg, K., Dincer H , Humbert M** et al., Pathophysiology of pulmonary hypertension due to lung disease , *Curr Opin Pulm Med.* 2003 ;9:131-138.
- **Rabe KF, Tenor H, Dent G,** et al., Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. *Am J Physiol* 1994;266:536-543.
- **Raja SG, Nayak SH , Chandrasekaran K** et al., Sildenafil: Emerging cardiovascular indications. *Ann Thorac Surg,* 2004; 78:1496-1506.
- **Rajfer J, Aronson WJ, Bush PA** et al., Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. *New England Journal of Medicine* 1992;327:2158-2162.
- **Ramakrishna G, Sprung J, Ravi BS** et al., Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of

Referances

- perioperative morbidity and mortality. *J Am Coll Cardiol.* 2005 ;45:1691-1699.
- **Reffellmann T, Kloner RA, Dorey FJ** et al.,Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. *Circulation* 2003;108:239- 244.
 - **Reffellmann T , Kloner RA, Ignarro LJ** et al., Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. *Cardiovascular Research* 2003;59:441-449.
 - **Reiter CD, Wang X, Tanus-Santos JE** et al.,Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. *Nat Med* 2002;8:1383-1389.
 - **Rich S, Dantzker DR, Ayres SM** et al.,Primary pulmonary hypertension. A national prospective study. *Ann Intern Med* 1987;107:216-223.
 - **Rich S, Kaufmann E, Levy PS** et al.,The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. *N Engl J Med.* 1992;327:76-81.
 - **Rich S, McLaughlin VV, Bergofsky EH** et al.,The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. *J Am Coll Cardiol.* 1999;34:1184-1187.
 - **Rich S, Kaufmann E, Levy PS** et al.,. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992;377;3251-3257.
 - **Rohde F. Colombo A. Goldraich S** et al., Effects of 50-Phosphodiesterase Four-Week Long Inhibition With Sildenafil in

Referances

Patients with chronic heart failure: a double-blind, placebo-controlled clinical trial . *Journal of Cardiac Failure* 2008 ;.14:189-197.

- **Rosengarten B, Schermuly RT, Voswinckel R** et al.,Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. *Cerebrovasc Dis.* 2006;21:194-200.
- **Rossi R, Annachiara N, Antonella L** et al., Sildenafil improves endothelial function in patients with pulmonary hypertension *Pulm Pharmacol Ther.* 2007;:172-177.
- **Rubens C, Ewert R, Halank M** et al.,Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. *Chest.*2001;120:1562-1569.
- **Rubin IJ, , Wensel R, Orzechowski H-D** et al.,Primary pulmonary hypertension, *N Engl Med* 1997;335:659-660.
- **Rubin LJ, Badesch DB, Barst RJ** et al.,Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med.* 2002;346:896-906.
- **Ryan J. Tedford, MD; Anna R** et al., PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support, 2008;4:213-219.
- **Salloum F, Yin C, Xi L** et al., Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. *Circulation Research*2003;92:595-599.
- **Sanchez LS, De la Monte SM, Filippov G** et al., Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. *Pediatr Res* 1998; 43:163-168.

Referances

- **Sandoval J, Gaspar J, Pulido T** et al., Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. *J Am Coll Cardiol.* 1998;32:297-304.
- **Sastry BK, Narasimhan C, Reddy NK,** et al., A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. *Indian Heart J* 2002;54:410-414.
- **Sastry BK, Narasimhan C, Reddy NK,** et al Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo controlled, double-blind, crossover study. *J Am Coll Cardiol* 2004; 43:1149- 1153.
- **Schermuly RT, Kreisselmeier KP, Ghofrani HA,** et al., Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. *Am J Respir Crit Care Med* 2004;169:39-45.
- **Schermuly RT, Pullamsetti SS, Kwapiszewska G,** et al., Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. *Circulation* 2007; 115:2331-2339.
- **Schoeffter P, Lugnier C, Demesy-Waeldele F,** et al., Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. *Biochem Pharmacol* 1987; 36:3965-3972.
- **Sebkhii A, Strange JW, Phillips SC** et al., Phosphodiesterase type 5 as a target for the treatment of hypoxia- induced pulmonary hypertension. *Circulation* 2003;107:3230-3235.
- **Senzaki H, Smith CJ, Juang GJ** et al., Cardiac phosphodiesterase 5 (cGMPspecific) modulates beta-adrenergic signaling in vivo and is downregulated in heart failure. *FASEB J.* 2001;15:1718-1726.

Referances

- **Sheth A, Park J, Madden** et al., Early haemodynamic benefit of Sildenafil in patient with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction *Ann Inter Med* 2005;43:2154-2158.
- **S. Alp, M. Skrygan, W.E. Schmidt** et al., Sildenafil improves hemodynamic parameters in COPD an investigation of six patients *Pulmonary Pharmacology & Therapeutics* 2005;19: 386-390.
- **Simonneau G, Barst RJ, Naeije R** et al., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2002;165:800-804.
- **Simonneau G, Galiè N, Rubin LJ, Langleben D** et al., Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004; 43: S5S-12S.
- **Simonneau G, Robbins I, Beghetti M** et al., Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2009; 54:S43-54.
- **Sitbon O, Humbert M, Jais X** et al., Long-term response to calcium channel blocke in idiopathic pulmonary arterial hypertension. *Circulation* 2005 ;111:3105-3111.
- **Sitbon O, Humbert M, Nunes H** et al., Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *J Am Coll Cardiol.* 2002 ; 40:780-788.
- **Sitbon O, Lascoux-Combe C, Delfraissy JF** et al., Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *Am J Respir Crit Care Med* 2008 ; 177: 108-111.

Referances

- **Stocker C, Penny DJ, Brizard CP**, et al Intravenous sildenafil and inhaled nitric oxide: A randomised trial in infants after cardiac surgery. *Intensive Care Med* 2003;42:1142-1148.
- **Stiebellehner L, Petkov V, Vonbank K** et al., Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. *Chest*. 2003;123:1295:1298.
- **Steiner MK, Preston IR, Klinger JR** et al .,Pulmonary hypertension: Inhaled nitric oxide, sildenafil and natriuretic peptides. *Curr Opin Pharmacol* 2005; 5:245-250.
- **Stephen L. Archer, M.D., and Evangelos D. Michelakis, M.D.** et al.,Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension *Eur Heart J* 2009;30:256-265.
- **Stewart DJ, Levy RD, Cernacek P** et al.,Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? *Ann Intern Med*. 1991;114:2154-2159.
- **Swissa M, Ohara T, Lee MH** et al., Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. *American Journal of Physiology* 200251: H1787-H1792 .
- **Tapson VF, Gomberg-Maitland M, McLaughlin VV** et al.,Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. *Chest*. 2006 ;129(3):683-688.

Referances

- **Tedford RJ, Hemnes AR, Russel SD** et al., PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. *Circ Heart Fail* 2008; 4:213-219.
- **Tongers J, Schwerdtfeger B, Klein G, Kempf T** et al., Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. *Am Heart J* 2007; 153:127-132.
- **Traverse JH, Chen YJ, Du R,** et al: Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. *Circulation* 102:2997-3002, 2000
- **Trebath R, Thomson J, Machado R** et al.,Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. *N Engl J Med.* 2001 ;345:367-371.
- **Tuder RM, Abman SH, Braun T** et al.,Pulmonary circulation: development and pathology. *J Am Coll Cardiol* 2009; 54:3-9.
- **Tuder RM, Chacon M, Alger L** et al.,Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. *J Pathol.* 2001; 195:367-374.
- **Tuder RM, Groves BM, Badesch DB** et al.,Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. *Am J Pathol.* 1994
- **Vallerie V,McLaughlin and Michael D** et al., Pulmonary Arterial Hypertension *Circulation* 2006 ;144: 275–285.
- **Vardi Y, Bulus M, Reisner S** et al.,Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile

Referances

dysfunction and cardiovascular disease. *European Urology* 2003;43:441-590.

- **Wallis RM , Nassar S, Aboud L** et al., The pharmacology of sildenafil, a novel selective inhibitor of phosphodiesterase (PDE) type 5. *Nippon Yaku-rigaku Zasshi. Japanese Journal of Pharmacology* 1999;114: 22P-26P.
- **Wang C, Wang J, Zhao L, Sprecher E** et al. Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca²⁺ entry. *J Pharmacol Sci* 2009; 108:71-78.
- **Weir EK, Reeve HL, Huang JM** et al., Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. *Circulation.* 1996 ;94:2216-2220.
- **Weiss BM, Zemp L, Seifert B** et al., Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. *J Am Coll Cardiol.* 1998;31:1650-1657.
- **Wharton J, Strange JW, Hess OM** et al., Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. *Am J Respir Crit Care Med* 2005;173:499-505.
- **Wilkins H, Guth A, Konig J** et al., Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. *Circulation* 2001 ;104:1218-1222.
- **Wilkins MR, Rabinovitch M, Sprecher F** et al., Emerging concepts and translational priorities in pulmonary arterial hypertension. *Circulation* 2008;118:1486-1495.

Referances

- **Yanagisawa M, Kurihara H, Kimura S** et al.,A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. 1988 ;132:263–270.
- **Yuan JJ, Aldinger AM, Juhaszova M** et al.,Dysfunctional voltage-gated K⁺ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. *Circulation*. 1998;113:2630-2641.
- **Zhang L, Zhang Z, Zhang RL** et al.,a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke, *Brain Res*. 2006; 1118:192-198.
- **Zhao TC, Tomobe Y, Kobayashi M** et al.,Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF-kappa B, iNOS and mitochondrial K(ATP) channel. *Journal of Molecular and Cellular Cardiology*, 2002; 34:263-377.
- **Zhao L, Mason NA, Morrell NW**, et al., Sildenafil inhibits hypoxia-induced pulmonary hypertension. *Circulation* 2001; 104:424-428.
- **Zhao YD, Courtman DW, Deng Y** et al.,Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. *Circ Res*. 2005 ;96:442-450.
- **Zusman RM, Morales A, Glasser DB**, et al .,Overall cardiovascular profile of sildenafil citrate. *Am J Cardiol* 1999;83:35C-44C.

Referances
